MORPHOSYS: MOR’s full focus on hemato-oncology makes it an ideal target for Incyte | BUY vs. NEUTRAL | EUR112 VS. EUR115 (+65%)
MORPHOSYS - BUY vs. NEUTRAL | EUR112 VS. EUR115 (+65%)MOR’s full focus on hemato-oncology makes it an ideal target for Incyte
A transformative deal with many layers
Current SOC in myelofibrosis leaves room for improvement
Pelabresib on its way to establish itself as a backbone treatment in MF
Pelabresib is evaluated in both first and second-line setting
Combination of pelabresib and Jakafi showed synergy in 1L setting
Arm 1 is confirming monotherapy activity of pelabresib
Arm 2 makes pelabresib + ruxolitinib combination the preferred strategy in the 2nd setting
Pivotal phase III MANIFEST-2 in first-line setting is currently enrolling
A USD1.8bn market opportunity at peak
Pelabresib fits quite naturally in MorphoSys’ pipeline
A merger between Incyte and MorphoSys has never made more sense
Back to BUY rating with a new EUR112 TP
Click here to download
MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.